Regulus Therapeutics (United States)
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Regulus Therapeutics (United States), United States, covering academic research published from 2008 to 2023. Read More.
Open Access Percentage
58%
Total
Publications
154
Total Open
Publications
90
Total
Citations
19K
Open Access
Percentage
58%
Total
Publications
154
Total Open
Publications
90
Total
Citations
19K
Breakdown
Publisher Open
8%
Both
34%
Other Platform Open
16%
Closed
42%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 29%
19
Hybrid 27%
18
No Guarantees 44%
29
Other Platform Open
Domain 88%
68
Institution 30%
23
Public 21%
16
Other Internet 16%
12
Preprint 6%
5
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 68 |
Europe PMC | Domain | 55 |
DOI | Other Internet | 27 |
Semantic Scholar | Public | 10 |
Figshare | Public | 9 |
California Institute of Technology - CaltechAUTHORS | Institution | 6 |
California Digital Library - eScholarship | Other Internet | 6 |
Harvard University - Digital Access to Scholarship at Harvard (DASH) | Institution | 5 |
bioRxiv | Preprint | 5 |
Le Centre pour la Communication Scientifique Directe - HAL - Diderot | Institution | 3 |